The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: A multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders

Psychopharmacology

Volumn 233, Issue 6, 2016, Pages 1087-1096

  Hassanzadeh, Parichehr ^a,b   Arbabi, Elham ^c   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Brain; Endocannabinoid system; Nerve growth factor; Rat; Resveratrol

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AMITRIPTYLINE; CLONAZEPAM; ENDOCANNABINOID; NERVE GROWTH FACTOR; RESVERATROL; ANTIOXIDANT; BORNANE DERIVATIVE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; STILBENE DERIVATIVE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN STEM; CONTROLLED STUDY; DRUG MECHANISM; EMOTION; FRONTAL CORTEX; HIPPOCAMPUS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; WISTAR RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

AMITRIPTYLINE; ANIMALS; ANTIOXIDANTS; BORNANES; BRAIN; CANNABINOIDS; CLONAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; MALE; NERVE GROWTH FACTOR; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; STILBENES;

EID: 84958817388     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-4188-3     Document Type: Article

References (80)

1. Abalo R, Cabezos PA, Vera G, Fernandez-pujol R, Martin MI (2010) The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat. Neurogastroenterol Motil 22:694-e206
2. Ahmeda RF, Abdel-Rahmana RF, Abdallaha HMI, Saleha DO, Farid OAHA, Hessin AF (2014) Antidepressant-like effect of resveratrol in a subchronic model of depression. J Arab Soc Med Res 9:48-53
3. Aloe L, Rocco ML, Balzamino BO, Micera A (2015) Nerve growth factor: a focus on neuroscience and therapy. Curr Neuropharmacol 13:294-303
4. Bambico FR, Duranti A, Tontini A, Tarzia G, Gobbi G (2009) Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Des 15:1623-1646
5. Banasr M, Valentine GW, Li XY, Gourley SL, Taylor JR, Duman RS (2007) Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiatry 62:496-504
6. Baumeister H, Harter M (2007) Prevalence of mental disorders based on general population surveys. Soc Psychiatry Psychiatr Epidemiol 42:537-546
7. Berton O, Nestler EJ (2006) New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137-151
8. Bonnafous C, Martinez J, Fargeas MJ, Buéno L (1993) Clonazepam-induced intestinal motor disturbances are linked to central nervous system release of cholecystokinin in rats. Eur J Pharmacol 237:237-242
9. Bournival J, Quessy P, Martinoli MG (2009) Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol 29:1169-1180
10. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
11. Bureau G, Longpré F, Martinoli MG (2008) Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res 86:403-410
12. Castren E, Voikar V, Rantamaki T (2007) Role of neurotrophic factors in depression. Curr Opin Pharmacol 7:18-21
13. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ (2014) Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12:2092-2103
14. Chadwick W, Mitchell N, Caroll J, Zhou Y, Park SS, Wang L, Becker KG, Zhang Y, Lehrmann E, Wood WH, Martin B, Maudsley S (2011) Amitriptyline-mediated cognitive enhancement in aged 3 × Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PLoS ONE 6:e21660
15. Cheng S, Ma M, Ma Y, Wang Z, Xu G, Liu X (2009) Combination therapy with intranasal NGF and electroacupuncture enhanced cell proliferation and survival in rats after stroke. Neurol Res 31:753-758
16. Conner JM, Franks KM, Titterness AK, Russell K, Merrill DA, Christie BR, Sejnowski TJ, Tuszynski MH (2009) NGF is essential for hippocampal plasticity and learning. J Neurosci 29:10883-10889
17. de Lago E, Petrosino S, Valenti M, Morera E, Ortega-Gutierrez S, Fernandez-Ruiz J, Di Marzo V (2005) Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol 70:446-452
18. di Matteo V, di Mascio M, di Giovanni G, Esposito E (2000) Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin 2C receptors. Psychopharmacology (Berl) 150:45-51
19. 1 inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala. Neuropharmacology 62:192-199
20. Dutta AK, Gopishetty B, Gogoi S, Ali S, Zhen J, Reith M (2011) The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents. Eur J Pharmacol 671:39-44
21. Ebendal T (1992) Function and evolution in the NGF family and its receptors. J Neurosci Res 32:461-470
22. Ereshefsky L (2009) Drug-drug interactions with the use of psychotropic medications: questions and answers. CNS Spectr 14:1-8
23. Fan E, Zhang L, Jiang S, Bai Y (2008) Beneficial effects of resveratrol on atherosclerosis. J Med Food 11:610-614
24. 1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats. Alcohol Clin Exp Res 34:131-141
25. Erlund I, Koli R, Alfthan G, Marniemi J, Puukka P, Mustonen P, Mattila P, Jula A (2008) Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. Am J Clin Nutr 87:323-331
26. Ge JF, Peng L, Cheng JQ, Pan CX, Tang J, Chen FH, Li J (2013) Antidepressant-like effect of resveratrol: involvement of antioxidant effect and peripheral regulation on HPA axis. Pharmacol Biochem Behav 114-115:64-69
27. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102:18620-18625
28. Gwinn RP, Kondratyev A, Gale K (2002) Time-dependent increase in basic fibroblast growth factor protein in limbic regions following electroshock seizures. Neuroscience 114:403-409
29. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R (2004) Neuroprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 141:997-1005
30. Hassanzadeh P (2010) The endocannabinoid system: critical for the neurotrophic action of psychotropic drugs. Biomed Rev 21:31-46
31. Hassanzadeh P, Hassanzadeh A (2010) Effects of different psychotropic agents on the central nerve growth factor protein. Iran J Basic Med Sci 13:202-209
32. Hassanzadeh P, Rahimpour S (2011) The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology 215:129-141
33. Hassanzadeh P, Hassanzadeh A (2011a) Involvement of the neurotrophin and cannabinoid systems in the mechanisms of action of neurokinin receptor antagonists. Eur Neuropsychopharmacol 21:905-917
34. Hassanzadeh P, Hassanzadeh A (2011b) The role of the endocannabinoids in suppression of the hypothalamic-pituitary-adrenal axis activity by doxepin. Iran J Basic Med Sci 14:414-421
35. 1 receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin. Neurochem Res 37:1112-1120
36. 1 receptors mediate the gastroprotective effect of neurotensin. Iran J Basic Med Sci 15:803-810
37. Hassanzadeh P, Hassanzadeh A (2013) Implication of NGF and endocannabinoid signalling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential. Psychopharmacology 229:571-578
38. Hellweg R, Hock C, Hartun HD (1989) An improved rapid and highly sensitive enzyme immunoassay for nerve growth factor. Tech J Meth Cell Mol Biol 1:43-49
39. Hellweg R, Thomas H, Arnswald A, von Richthofen S, Kay S, Fink H, Morgenstern R, Hörtnagl H (2001) Serotonergic lesion of median raphe nucleus alters nerve growth factor content and vulnerability of cholinergic septohippocampal neurons in rat. Brain Res 907:100-108
40. Hellweg R, Lang UE, Nagel M, Baumgartner A (2002) Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Mol Psychiatry 7:604-608
41. Hoener MC, Hewitt E, Conner JM, Costello JW, Varon S (1996) Nerve growth factor (NGF) content in adult rat brain tissues is several-fold higher than generally reported and is largely associated with sedimentable fractions. Brain Res 728:47-56
42. Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Ann Rev Neurosci 24:677-736
43. Hurley LL, Akinfiresoye L, Kalejaiye O, Tizabi Y (2014) Antidepressant effects of resveratrol in an animal model of depression. Behav Brain Res 268:1-7
44. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G, Ye K (2009) The antidepressant amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol 16:644-656
45. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B (2004) Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 19:1691-1698
46. Kodali M, Parihar VK, Hattiangady B, Mishra V, Shuai B, Shetty AK (2015) Resveratrol prevents age-related memory and mood dysfunction with increased hippocampal neurogenesis and microvasculature, and reduced glial activation. Sci Rep 5(8075):1-16
47. Koga D, Santa T, Fukushima T, Homma H, Imai K (1997) Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogues in rat brain and peripheral tissues. J Chromatogr B Biomed Sci Appl 690:7-13
48. Lad SP, Neet KE, Mufson EJ (2003) Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2:315-334
49. McLaughlin RJ, Gobbi G (2012) Cannabinoids and emotionality: a neuroanatomical perspective. Neuroscience 204:134-144
50. Marsicano G, Lutz B (2006) Neuromodulatory functions of the endocannabinoid system. J Endocrinol Investig 29:27-46
51. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA (2006) The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 147:873-885
52. Miwa T, Moriizumi T, Horikawa I, Uramoto N, Ishimaru T, Nishimura T, Furukawa M (2002) Role of nerve growth factor in the olfactory system. Microsci Res Tech 58:197-203
53. Moises HC, Womble MD, Washburn MS, Williams LR (1995) Nerve growth factor facilitates cholinergic neurotransmission between nucleus basalis and the amygdala in rat: an electrophysiological analysis. J Neurosci 15:8131-8142
54. Nemeroff CB (2007) The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 41:189-206
55. Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462
56. Patel S, Rademacher DJ, Hillard CJ (2003) Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 306:880-888
57. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215:161-169
58. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. Academic, San Diego
59. Pirola L, Frojdo S (2008) Resveratrol: one molecule, many targets. IUBMB Life 60:323-332
60. 1 receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J Neurochem 108:1423-1433
61. Saha L, Amitava C (2014) Understanding the anti-kindling role and its mechanism of resveratrol in pentylenetetrazole induced-kindling in a rat model. Pharmacol Biochem Behav 120:57-64
62. Shaltiel G, Chen G, Manji HK (2007) Neurotrophic signalling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 7:22-26
63. Sun AY, Wang Q, Simonyi A, Sun GY (2010) Trans-resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 41:375-383
64. Suzuki Y, Wang L, Edge J, Mimaki T, Walson PD (1994) Anticonvulsant tolerance to clonazepam in amygdala kindled rats: clonazepam concentrations and benzodiazepine receptor binding. Neuropharmacology 33:869-874
65. Tanis KQ, Duman RS (2007) Intracellular signaling pathways pave roads to recovery for mood disorders. Ann Med 39:531-544
66. Timmers S, Auwerx J, Schrauwen P (2012) The journey of resveratrol from yeast to human. Aging (Albany NY) 4:146-158
67. Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán FA, García-Conesa MT, Espín JC (2013) Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 19:6064-6093
68. van der Made SM, Plat J, Mensink RP (2015) Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS ONE 10:e0118393
69. van der Watt G, Laugharne J, Janca A (2008) Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry 21:37-42
70. Vinay P, KhanMohammad M, Alvin T, Sahebarao PM (2004) Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J Psychiat Res 38:521-529
71. Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331-342
72. Viveros MP, Marco EM, Liorente R, Lopez-Gallardo M (2007) Endocannabinoid system and synaptic plasticity: implication for emotional response. Neural Plast 2007:52908
73. Wang Z, Gu J, Wang X, Xie K, Luan Q, Wan N, Zhang Q, Jiang H, Liu D (2013) Antidepressant-like activity of resveratrol treatment in the forced swim test and tail suspension test in mice: the HPA axis, BDNF expression and phosphorylation of ERK. Pharmacol Biochem Behav 112:104-110
74. Williams EJ, Walsh FS, Doherty P (2003) The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol 160:481-486
75. Winkler J, Ramirez GA, Thal LJ, Waite JJ (2000) Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors. J Neurosci 20:834-844
76. Xu Y, Wang Z, You W, Zhang X, Li S, Barish PA, Vernon MM, Du X, Li G, Pan J, Ogle WO (2010) Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 20:405-413
77. Yanpallewar SU, Fernandes K, Marathe SV, Vadodaria KC, Jhaveri D, Rommelfanger K, Ladiwala U, Jha S, Muthig V, Hein L, Bartlett P, Weinshenker D, Vaidya VA (2010) α2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J Neurosci 30:1096-1109
78. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW, Klein S (2012) Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 16:658-664
79. Yu Y, Wang R, Chen C, Du X, Ruan L, Sun J, Li J, Zhang L, O'Donnell JM, Pan J, Xu Y (2013) Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. J Psychiatr Res 47:315-322
80. Zhong LM, Zong Y, Sun L, Guo JZ, Zhang W, He Y, Song R, Wang WM, Xiao CJ, Lu D (2012) Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS ONE 7:e32195